Paris Course On Revascularization In Brief
This article was originally published in The Gray Sheet
Executive Summary
Enter CoStar: Cobalt-chromium paclitaxel-eluting stent is associated with 2.9% target lesion revascularization (TLR) rate and 7.6% major adverse event rate in 12-month follow-up results of 145-patient EuroSTAR trial, presented by Keith Dawkins, MD, Southampton University Hospital, England. The firm recently launched the 1,700-patient, 90-site COSTAR-II pivotal study. The non-inferiority trial compares CoStar with Boston Scientific's Taxus (1"The Gray Sheet" May 16, 2005, p. 17)...